Initially developed in 2012 by Novo Nordisk, it started as an extended-duration alternative to Liraglutide
The medication doesn't enhance athletic performanceinstead, it removes psychological barriers to consistent physical activity by eliminating constant hunger and food cravings that derail workout motivation
Semaglutide, a selective GLP-1 receptor agonist marketed as Ozempic, Wegovy, and Rybelsus, is one of the most extensively studied anti-obesity and anti-diabetes medications in history, with over 25,000 clinical trial participants and FDA approval for three distinct indications
Softgel (gelatin, glycerin, purified water), medium chain triglycerides, methylsulfonylmethane, xylitol, non-GMO sunflower lecithin, peppermint oil, Stevia rebaudianaleaf